- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01006720
Sugammadex and Neostigmine at Residual Neuromuscular Blockade (SUNDRO20)
Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)
Study Overview
Status
Intervention / Treatment
Detailed Description
Muscle relaxants are integral part of modern anesthesia. They optimize intubating conditions, reduce laryngeal trauma and improve operating conditions. Drawback is a possible pharmacological (muscle relaxing) effect of these drugs beyond the end of the operation (i.e. post-operative residual curarization: PORC). Reportedly about 30% of all patients who received muscle relaxants show signs of PORC when arriving in the post-anesthesia care unit. PORC comprises the risk of impaired post-operative fine motor and coordinative skills with a possible impairment of swallowing pharyngeal secretions with an increased risk of aspiration after extubation. Possible deleterious effects of this could be pneumonia, bronchitis, myocardial infarction, cardiac insufficiency, stroke or re-operation.
In order to avoid PORC patients with residual neuromuscular block receive a muscle relaxant antagonist from the anesthesiologist at the end of the operation. However, these drugs (neostigmine, pyridostigmine, etc.) from the class of cholinesterase inhibitors have unwanted effects such as bradycardia, increased gastro-intestinal motility, post-operative nausea and vomiting, salivation etc. To decrease these unwanted side effects cholinesterase inhibitors have to be given in combination with parasympatholyics e.g. atropine or glycopyrrolate with their own spectrum of unwanted side effects.
From October 2008 on, Sugammadex, a completely new reversal drug was introduced in to clinical practice. Sugammadex, is a modified γ-cyclodextrine able to specifically bind rocuronium (a steroidal muscle relaxant). The complex is eliminated via the kidneys. However, all studies so far have focussed on reversal of profound or deep neuromuscular blockade. This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either the neostigmine or sugammadex.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Bavaria
-
Munic, Bavaria, Germany, 81675
- Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients ASA physical status I - III
- Patients over 18 years
- Patients scheduled for general anesthesia with intubation using rocuronium
- Patients having given informed consent to the study
Exclusion Criteria:
- Anatomic and functional malformations with expected difficult intubation
- Known or suspected neuromuscular disease
- Significant hepatic or renal dysfunction
- Known or suspected history or family history of disposition to malignant hyperthermia
- Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other drugs used for general anesthesia
- Use of drugs that interfere with muscle relaxants
- Patients, included in another trial within the last 30 days
- Patients, with legal guidant
- Patients with contraindication towards the use of Sugammadex, neostigmine or glycopyrrolate
- Patients, which have already participated in a sugammadex trial
- Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen, status post tubal ligation)
- Breastfeeding women
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sgx 0.25
Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
|
Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25) |
Sgx 0.5
Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
|
Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25) |
Sgx 0.75
Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
|
Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25) |
Sgx 1.0
Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
|
Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25) |
Sgx 1.25
Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
|
Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25) |
Neo 10
Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
|
Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
|
Neo 25
Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
|
Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
|
Neo 40
Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
|
Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
|
Neo 55
Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
|
Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
|
Neo 70
Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
|
Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
|
Saline
Saline group: Saline as placebo
|
Saline 0.9% (Saline)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to TOF-ratio 0.9 following the investigational drug
Time Frame: Regular anesthesia time, approximately 1.5 hours
|
Regular anesthesia time, approximately 1.5 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Heidrun Fink, PD Dr., MD, Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München
Publications and helpful links
General Publications
- Puhringer FK, Rex C, Sielenkamper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008 Aug;109(2):188-97. doi: 10.1097/ALN.0b013e31817f5bc7.
- Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008 Nov;109(5):816-24. doi: 10.1097/ALN.0b013e31818a3fee.
- Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2.
- Kaufhold N, Schaller SJ, Stauble CG, Baumuller E, Ulm K, Blobner M, Fink H. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)dagger, Br J Anaesth. 2016 Feb;116(2):233-40. doi: 10.1093/bja/aev437.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Delayed Emergence from Anesthesia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Cholinesterase Inhibitors
- Parasympathomimetics
- Neostigmine
Other Study ID Numbers
- SUNDRO20
- EudraCT number 2009-013499-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Residual Neuromuscular Block (TOF-ratio of 0.2)
-
Erasme University HospitalCompleted
-
Universitair Ziekenhuis BrusselRecruitingAnalyse Neuromuscular Monitoring for Developing a Model to Predict TOF Ratio During AnesthesiaBelgium
-
Hospital do Divino Espírito Santo de Ponta DelgadaCompletedAnesthesia | Neuromuscular Blockade | TOF | Curarization, Postoperative ResidualPortugal
-
Seoul National University Bundang HospitalCompletedNeuromuscular Block, ResidualKorea, Republic of
-
University of ValenciaHospital General Universitario Gregorio Marañon; General University Hospital...CompletedIncomplete Reversal of Neuromuscular Block | Postoperative Respiratory ComplicationsSpain
-
Federal University of Minas GeraisCompleted
-
Pontificia Universidade Catolica de Sao PauloNot yet recruitingNeuromuscular Blockade | Neuromuscular Block, Residual | Neuromuscular Block Prolonged
-
Dr. Negrin University HospitalNot yet recruitingResidual Neuromuscular Block in the Post-Anesthetic Unit and Postoperative Complications (Porcerito)Postoperative Complications | Postoperative Neuromuscular BlockSpain
-
National Cardiovascular Center Harapan Kita Hospital...CompletedTetralogy of Fallot | Congenital Heart Disease | Outcome | TOF | Neutrophil-lymphocyte Ratio | Absolute Lymphocyte Count | Thrombocyte-lymphocyte RatioIndonesia
-
Azienda Ospedaliera di PadovaCompletedPostoperative Residual Curarization | Residual Neuromuscular BlockItaly
Clinical Trials on Sugammadex
-
University Health Network, TorontoMerck Sharp & Dohme LLCCompletedPosterior Cervical Decompression and FusionCanada
-
Seoul National University HospitalRecruitingPostoperative Residual CurarizationKorea, Republic of
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCRecruitingPostoperative Urinary RetentionUnited States
-
Severance HospitalCompletedAnesthesia Recovery Period, Neuromuscular BlockadeKorea, Republic of
-
University of AthensUnknownSurgical Procedure, UnspecifiedGreece
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedProstate Cancer | Neuromuscular BlockadeItaly
-
Merck Sharp & Dohme LLCCompletedRenal Insufficiency | Renal ImpairmentUnited States
-
Hopital FochCompleted
-
Beijing Tiantan HospitalCompletedSugammadex | Motor Evoked PotentialsChina
-
Merck Sharp & Dohme LLCCompleted